SVRE vs AEYE vs CELU vs GKOS vs INDI

For growth investors, Celularity Inc.

(CELU) is the stronger pick with 138. 1% revenue growth year-over-year, versus -38. 1% for SaverOne 2014 Ltd (SVRE). Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.

5%, compared to -100. 0% for SaverOne 2014 Ltd (SVRE). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus SVRE's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SaverOne 2014 Ltd (SVRE) is the lower-risk stock at 1.

17β versus indie Semiconductor, Inc. 's 2. 71β — meaning INDI is approximately 133% more volatile than SVRE relative to the S&P 500. On balance sheet safety, AudioEye, Inc. (AEYE) carries a lower debt/equity ratio of 15% versus 8% for Celularity Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Celularity Inc.

(CELU) is pulling ahead at 138. 1% versus -38. 1% for SaverOne 2014 Ltd (SVRE). On earnings-per-share growth, the picture is similar: Celularity Inc. grew EPS 76. 0% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, SVRE leads at 55. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AudioEye, Inc.

(AEYE) is the more profitable company, earning -7. 6% net margin versus -20. 8% for SaverOne 2014 Ltd — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -1975. 8% for SVRE. At the gross margin level — before operating expenses — AEYE leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Glaukos Corporation (GKOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

20), +457. 1% 10Y return). indie Semiconductor, Inc. (INDI) carries a higher beta of 2. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GKOS: +457. 1%, INDI: -54. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SVRE (Technology) and AEYE (Technology) and CELU (Healthcare) and GKOS (Healthcare) and INDI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SVRE is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; CELU is a small-cap high-growth stock; GKOS is a small-cap high-growth stock; INDI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.